Bausch + Lomb Corporation reports developments across its global eye health business, including vision care, surgical devices and ophthalmic pharmaceuticals. Recurring updates cover contact lenses and lens care products, eye vitamins and redness-relief drops, dry eye and prescription ophthalmology brands, intraocular lenses, vitrectomy cutters and the Stellaris Elite Vision Enhancement System.
Company news also includes financial results and guidance, scientific presentations, R&D pipeline discussions, FDA 510(k) clearances, European product launches and sustainability programs such as ONE by ONE Recycling. Product-specific coverage frequently references Biotrue, LUMIFY, XIIDRA, MIEBO, PreserVision, INFUSE, ULTRA ONE DAY, enVista and Bi-Blade technologies.
Bausch + Lomb (BLCO) plans to begin its clinical development program for investigational oral dry AMD treatment BL1243 in 2027.
BL1243, also called tonabersat, is being developed for earlier-stage dry age-related macular degeneration, an eye disease. Following an FDA meeting, the company said it had greater clarity on the development path. The FDA supported, in principle, the proposed initial study design, which will examine how the medicine behaves in the body and assess safety.
Barring unexpected findings, initial study results are expected to support advancement into a Phase 2 study involving dry AMD patients who have not yet developed advanced retinal damage. Bausch + Lomb sees a potential oral treatment option for earlier-stage disease if development succeeds and approval is obtained; the meeting was not a treatment approval.
Bausch + Lomb (BLCO) will release its third-quarter 2026 financial results on Oct. 28 and host a call that morning. The conference call and live webcast begin at 8 a.m. ET to discuss results and provide a business update. Materials will be available on the company's Investor Relations website before the call.
Bausch + Lomb (BLCO) received European CE Mark approval for its next-generation SeeLyra femtosecond laser platform for ophthalmic surgery. SeeLyra is described as one of the most compact femtosecond systems, designed to provide precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic procedures, while supporting efficient workflows in space-constrained operating rooms.
The platform integrates live swept source OCT for real-time depth visualization and precise positioning of laser cuts, and retains features from the prior VICTUS platform such as an intuitive user interface and broad procedural adaptability. Its compact, mobile design without a fixed patient bed allows flexible positioning, compatibility with existing beds and may improve patient comfort. SeeLyra will be available in Europe on a limited basis in the coming months, with wider availability expected in 2027, and Bausch + Lomb is pursuing approvals in additional markets, including the United States.
Bausch + Lomb (BLCO) reported new published real‑world research on its enVista Aspire and enVista Aspire toric intraocular lenses for cataract patients.
The multicenter retrospective case series included 84 patients and 141 eyes (88 enVista Aspire, 53 enVista Aspire toric). In the enVista Aspire group, 97.2% of eyes achieved monocular corrected distance visual acuity (CDVA) of 20/25 or better, 71.3% uncorrected distance (UDVA) of 20/25 or better, and 76.6% uncorrected intermediate (UIVA) of 20/32 or better. In the toric group, 94.9% of eyes reached CDVA 20/25 or better, 84.9% UDVA 20/25 or better, and 93% UIVA 20/32 or better. All subjects in both groups achieved binocular UIVA of 20/32 or better, and no serious adverse events were reported. The lenses use intermediate‑optimized optics designed to broaden depth of focus beyond standard monofocal IOLs.
Bausch + Lomb (NYSE/TSX: BLCO) released results from its 2026 (Peri)Menopause Survey of 402 peri-, menopausal and post-menopausal women, showing a large awareness gap between menopause and dry eye disease.
Only 14% recognized dry eye as a menopause-related symptom versus 79% for hot flashes, and 78% were surprised to learn of the connection. Among women with dry eye during these stages, 80% said the symptom came as a surprise, and many reported functional impacts: 58% had difficulty reading, 53% using screens, 26% driving and 17% experienced reduced productivity. Bausch + Lomb highlighted its broad dry eye portfolio and ongoing education efforts, directing women to KnowYourDryEye.com for information.
Bausch + Lomb (NYSE/TSX: BLCO) reported clinical data for two first-in-class ophthalmic candidates and outlined advancement plans. A Phase 2 trial of its dual-action dry eye eye drop, combining 5% lifitegrast and perfluorohexyloctane, did not meet the Day 29 primary endpoint versus lifitegrast alone, but a pre-specified Day 15 analysis showed a statistically significant tCFS improvement (p=0.0007). Based on this, the company will move the program into Phase 3 using Day 15 as the primary endpoint.
The TRPV1 antagonist BL1332 showed positive Phase 1b results in a capsaicin-induced ocular pain model, with a 5.5-point pain reduction versus vehicle at five seconds and markedly shorter pain duration (1.6 vs 37.8 seconds). BL1332 is in Phase 2 for post-surgical pain, with topline results expected in the coming months. According to Bausch + Lomb, estimated combined peak sales for the dry eye therapy and BL1332 are about $2.1 billion, assuming successful development and commercialization beyond 2028.
Bausch Health (NYSE: BHC) announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of Bausch + Lomb (NYSE: BLCO), effective August 5, 2026. Bausch + Lomb is described as a key asset of Bausch Health.
Additional directors Robert J. Chersi, Laurence E. Paul, M.D., and Barbara J. Trebbi also joined the Bausch + Lomb board. They replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, who resigned without any stated disagreements with Bausch + Lomb. Bausch Health remains Bausch + Lomb’s largest shareholder, indirectly holding about 87% of its outstanding common shares, and requested these board changes in line with its ownership position.
Bausch + Lomb (NYSE/TSX: BLCO) announced Board changes effective Aug. 5, 2026, appointing four new directors at the request of majority owner Bausch Health, which holds approximately 87% of outstanding common shares. Four current directors resigned to facilitate the refresh, and the company said none resigned due to disagreement.
Bausch + Lomb reported second-quarter 2026 revenue of $1.394 billion, up 9% reported and 8% in constant currency versus 2025, with broad-based segment growth and margin expansion. Net operating cash flow rose from $32 million in Q1 to $153 million in Q2, while adjusted cash flow from operations increased from $45 million to $161 million. The company reaffirmed its previously raised 2026 guidance, targeting full-year revenue of $5.440–$5.540 billion and Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) of $1.025–$1.075 billion.
Bausch + Lomb (NYSE/TSX: BLCO) reported second-quarter 2026 revenue of $1.394 billion, up 9% reported and 8% in constant currency versus 2025, with growth across Vision Care, Surgical and Pharmaceuticals. Surgical revenue rose 19%, Pharmaceuticals 15% and Vision Care 4%.
Operating results shifted to $83 million of operating income from an $11 million loss, while GAAP net loss improved to $14 million from $62 million. Adjusted net income rose to $55 million and adjusted EBITDA excluding acquired IPR&D increased to $246 million. Cash flow from operations grew to $153 million from $35 million.
According to Bausch + Lomb, full-year 2026 guidance was raised to revenue of $5.44–$5.54 billion and adjusted EBITDA excluding acquired IPR&D of $1.025–$1.075 billion. The company also reported topline pivotal data for the enVista Beyond investigational IOL, showing improved intermediate vision and depth of focus versus a monofocal lens, a favorable safety profile and narrowly missed predefined performance targets.
Bausch + Lomb (NYSE/TSX: BLCO) announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery system designed for the enVista Aspire and Envy IOL families. EyeGility offers one-handed operation, balanced push force for smooth IOL delivery and a silicone soft-tipped plunger, allowing injection through a 2.4 mm incision and up to 20 minutes of standby time from preparation to lens delivery.
According to the company, EyeGility is now available in the U.S. with enVista Aspire preloaded IOLs, with enVista Envy lenses preloaded into EyeGility expected in the coming months. The release details indications, precautions, warnings and potential adverse events for the EyeGility inserter, enVista Aspire hydrophobic acrylic IOL and enVista Envy non-toric and toric hydrophobic acrylic IOLs, emphasizing physician judgment, patient selection and adherence to Directions for Use and federal law restrictions.